TEST DRAFT FABU #2
Investigation of a Medication Being Studied for Type 1 Diabetes
Study Overview
Eligibility Criteria
You may be eligible for this study if you meet the following criteria:
- Conditions: Type 1 Diabetes Mellitus
-
Age: 40 years - 60 years
-
Gender: All
- Participants who meet the criteria of T1D according to American Diabetes Association
- Initiated exogenous insulin replacement therapy not longer than 90 days prior to screening visit at which random C-peptide will be assessed (V1).
This study investigates an investigational medication for individuals with Type 1 diabetes (T1D). Type 1 diabetes is a chronic disease where the body's defense system mistakenly attacks specific cells within the pancreas, which make insulin. Insulin helps control sugar in the blood. When these cells are damaged, they cannot make enough insulin. This means people with Type 1 diabetes need to take insulin every day to keep their blood sugar at safe levels.
Participants in this study will receive either the investigational medication or a placebo. A placebo is an inactive substance that looks like the investigational medicine but does not contain any medicine. The study aims to assess the effects of the investigational medication on individuals with Type 1 diabetes.
- Who can participate: Adults diagnosed with Type 1 diabetes according to the American Diabetes Association guidelines and who have started insulin therapy within the last 90 days are eligible to participate.
- Study details: Participants will receive either the medication being studied or a placebo.